Has to make one wonder how many Keytruda patients came from Sunrise and allowing MOS to jump rivals, with a better priming of the immune system and allowing many more patients to respond with Keytruda
"...Merck raises stakes in lung cancer as rivals close in
Deena Beasley
(Reuters) - Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.
Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year."
Merck I believe already has stated it will not charge cost to patients to those who do not respond to Keytruda treatment and I don't see that approach unless they knew a shoe in type of way to prep and prime ones immune cells to respond to Keytruda
Hopefully all new Peregrine BOD members digging much deeper into things
News 
Market Data 
Discover 
